Document:

Exhibit 10.15

 Exhibit 10.15 
 Loan Agreement1 Modifications Term Sheet2 
 Set forth below are the revised terms (the “Term Sheet”) of the Loan Agreement the members of the ad hoc committee of lenders party to the Loan Agreement (the “Lenders”) have
indicated they will require in order to support and consent to the proposed restructuring of Primus Telecommunications Group, Incorporated (“Parent” or the “Company”), Primus Telecommunications Holding, Inc.
(“Holding”), Primus Telecommunications International, Inc (“PTII”) and Primus Telecommunications IHC, Inc. (“IHC”). 
  

			
	Waiver:	  	Pursuant to the Joint Plan of Reorganization of Parent, Holding, PTII and IHC (the “Plan”), the Loan Agreement shall be amended to waive all defaults arising out of the
bankruptcy proceedings (the “Proceedings”) of Parent, Holding, PTII, IHC and any of their subsidiaries.
		
	Guarantors:	  	 Will remain as Parent, Primus Telecommunications, Inc., PTII, Trescom International, Inc., Rockwell Communications Corporation, Least Cost
Routing, Inc., Trescom U.S.A., Inc., iPRIMUS USA, Inc., iPRIMUS.com, Inc. and IHC.
  
 Parent and the Borrower will provide a representation that (a) there are no domestic subsidiaries of the Company that are not Guarantors that account for, in the aggregate, 5% or more of consolidated assets or consolidated revenue of the
Company and (b) there are no Unrestricted Subsidiaries at the date of the amendment. The Loan Agreement shall be amended to prohibit designation of any Subsidiaries as Unrestricted Subsidiaries, provided however, that the Company may designate
Subsidiaries as Unrestricted Subsidiaries in connection with refinancing the Loans in their entirety.

  
  

	 1
	 Term Loan Agreement, dated as of February 18, 2005, as amended on March 18, 2005 and February 5, 2007,
among Primus Telecommunications Group, Incorporated, as Parent, Primus Telecommunications Holding, Inc., as Borrower, Lehman Brothers Inc., as Arranger, and Lehman Commercial Paper Inc., as Syndication Agent and Administrative Agent. Capitalized
terms not defined herein shall have the meaning ascribed to them pursuant to the Loan Agreement. 

	 2
	 Intentionally left blank. 

  

 1 

					
	Interest Rate:	  	 Beginning on the date of substantial consummation of the Plan (the “Effective Date”), the Interest Rate shall be
either (to be selected at the Company’s option with notification to the Lenders at least 30 days prior to each interest payment date) (i) LIBOR plus 900 bps with a LIBOR floor of 3% in cash, or (ii) LIBOR plus 700 bps with a LIBOR
floor of 3% in cash plus 400 bps in PIK.
  
 Subject to obtaining requisite
authority from the Bankruptcy Court3 and until the Effective Date, the Borrower or a Guarantor will continue to make interest payments in accordance
with the Loan Agreement at the interest rate currently applicable under the Loan Agreement.

		
	Amortization:	  	The amortization schedule set forth in Section 2.3 of the Loan Agreement will be amended as follows:

  

			
	 Installment
	  	Principal Amount
	March 31, 2009	  	$250,000
	June 30, 2009	  	$250,000
	September 30, 2009	  	$925,000
	December 31, 2009	  	$925,000
	March 31, 2010	  	$1,400,000
	June 30, 2010	  	$1,400,000
	September 30, 2010	  	$1,400,000
	December 31, 2010	  	$1,400,000
	February 18, 2011	  	Remaining outstanding
principal balance (including
all capitalized PIK
interest, if any).

  

					
		  	Subject to obtaining requisite authority from the Bankruptcy Court4 and until
the Effective Date the Borrower or a Guarantor will continue to make a minimum payment of $250,000 on each date set forth above in accordance with the terms of the existing Loan Agreement.

  
  

	 3
	 The Lenders’ forbearance during the Proceedings will be conditioned on there being no objections made with respect
to any such relief by the holders of the (i) Second Lien Debt (as defined herein), (ii) 8% Senior Notes issued by Holding, or (iii) 5% Exchangeable Senior Notes issued by Holding, or their respective indenture trustees.

	 4
	 The Lenders’ forbearance during the Proceedings will be conditioned on there being no objections made with respect
to any such relief by the holders of the (i) Second Lien Debt, (ii) 8% Senior Notes issued by Holding, or (iii) 5% Exchangeable Senior Notes issued by Holding, or their respective indenture trustees. 

  

 2 

			
	Consent Fee:	 	None.
		
	Administrative Agent:	 	No later than the Effective Date, Lehman Commercial Paper Inc. (“LCPI”) shall be replaced as Administrative Agent with a replacement agent reasonably acceptable to the
Company and the Lenders. Promptly upon the Term Sheet Agreement Date (as defined below), the Company will negotiate and finalize the terms of a release with LCPI and its affiliates relating to LCPI’s role as administrative agent, to be
effective no later than the Effective Date, reasonably consistent with similar releases that other borrowers have provided LCPI and its affiliates in connection with replacing LCPI as administrative agent, but shall reserve the Company’s and
affiliates’ claims relating to hedging transactions (the “Release”). The Release shall be effective upon the execution of the amendment to the Loan Agreement or such earlier date as may be agreed by the Company, LCPI and the
Lenders.
		
	Collateral:	 	Same collateral basket as under the Loan Agreement. Account control agreements for all of Borrower’s and Guarantors’ securities accounts and deposit accounts (other than (i) deposit
accounts and securities accounts holding cash and investment property in an aggregate amount, for all such accounts taken together, not exceeding $500,000, and (ii) the BofA Account referenced below) are to be delivered to the Lenders no later than
the Effective Date.
		
	Liens/Security Interest:	 	First priority liens in all of the Collateral, except for Permitted Liens.
		
	Covenants:	 	 •        Section 6.2(a) - Limitation on Indebtedness: Delete
all debt incurrence tests in Sections 6.2(a)(i), (ii) and (iii).
  
 •        Section 6.2(b) will be modified so that the only debt permitted is (1) existing and outstanding debt on the Term Sheet Agreement Date, (2) debt incurred in
connection with refinancing the Loans in whole but not in part (including the current amount of the Loans plus customary and reasonable fees associated with the refinancing or refinancing of the Loans), (3) an aggregate of $50 million of
Indebtedness pursuant to 6.2(b)(ii) at any time outstanding (of which approximately $40 million is currently outstanding), (4) intercompany indebtedness pursuant to 6.2(b)(iii), (5) refinancing indebtedness pursuant to 6.2(b)(iv),
(6)

  

 3 

			
		 	 permitted indebtedness (e.g. hedges) pursuant to 6.2(b)(v), (7) additional guarantees of the Loans pursuant to 6.2(b)(viii), (8)
temporary overdrafts pursuant to 6.2(b)(x), (9) plus an additional unsecured debt basket of up to an aggregate dollar cap of $7.5 million. No other Indebtedness shall be permitted to be incurred by the Loan Parties, except for additional debt
arising from (1) the use of PIK and/or (2) acquisitions which would be limited to 2.5 times annual trailing twelve month (“TTM”) Adjusted EBITDA acquired (as calculated by the Company and such adjustments shall be subject to agreed upon
procedures performed by the Company’s independent accountants) and as long as such debt is either (a) subordinated to the Loans and the Second Lien Debt (as defined below) in right of payment and rights in the Collateral, with maturity after
the 91st day after maturity of the Loans, (b) debt of the acquisition entity that is non-recourse as to Parent or any Restricted Subsidiary other
than the Restricted Subsidiary incurring the subject Indebtedness; provided, however, that non-recourse debt issued by any Restricted Subsidiary pursuant to clause (b) shall not exceed $52.5 million in the aggregate, or (c) additional
Second Lien Debt so long as such Second Lien Debt is subordinated in right of payment to the Loans, or any combination of (a), (b) and (c) above, and, in each case, the acquired assets (other than assets of Foreign Subsidiaries) are part of the
Collateral securing the Loans in which the Lenders have a first priority security interest and with respect to acquisitions involving a Foreign Subsidiary the Loans would be secured by a pledge of 65% of the stock of such entity or parent entity;
provided further that, in each such case, the purchase price of any acquisition of assets of a Foreign Subsidiary is funded from Indebtedness permitted to be incurred pursuant to the debt covenant and, as necessary, from one or more of
the following sources: (i) Parent equity issued to the seller; (ii) cash from issuance of Parent equity; and (iii) cash acquired in the acquisition.
  
 •        Section 6.2(d) - Limitation on Indebtedness: to be modified such that all
Guarantees, other than Guarantees made by Parent or a Restricted Subsidiary for the benefit of the Lenders under the Loan Documents, will be counted against the Limitation on

  

 4 

			
		 	 Indebtedness covenant, and shall only be permitted to the extent of availability under the Limitation on Indebtedness
covenant; provided however, that for such purposes such Guarantees and the related debt are not both counted.
  
 •        Section 6.3(iii) - Restricted Payments Covenant to be modified to make
clear that any voluntary or optional principal payment, or voluntary or optional redemption, repurchase, defeasance, or other acquisition or retirement for value of any debt, including but not limited to any of the 14 1/4% Senior Secured Notes issued by IHC (the “Second Lien Debt”), other than Indebtedness representing the Loans and
Indebtedness pursuant to Section 6.2(b)(ii), will be a “Restricted Payment”; provided that “Restricted Payments” shall not include (a) any repayment, repurchase or retirement of any indebtedness in connection with any
refinancing permitted by Section 6.2(b)(iv) (as amended as provided herein) or (b) any repurchase of Indebtedness with equity proceeds or Asset Sale proceeds not otherwise required to be applied in prepayment of the Loans. Except as otherwise set
forth in this Term Sheet, the Restricted Payments covenant to be modified in its entirety to contain only customary restrictions for bank credit agreements of this type in the current market, and for the avoidance of doubt, among other items, the
modifications shall include, (i) the deletion of incurrence test and the building basket concept, (ii) the deletions of clauses (b), (d), (g), (i), (k), (l) and (m) in the second paragraph of Section 6.3 and (iii) the only catch-all basket shall be
a general basket limited to a cap of $1 million.
  
 •        Section 6.7 - Limitation on Liens covenant to be modified to delete incurrence test and expressly prohibit any Liens other than Permitted Liens.
  
 •        Section 6.12 - Restriction on Certain Purchases of Indebtedness: to be modified to preclude Parent, Borrower and each Restricted Subsidiary from repaying, prepaying or purchasing debt,
excluding debt incurred under 6.2(b)(ii); provided that the $1 million Restricted Payments basket may be used to repay, prepay or purchase other debt including Second Lien Debt if no Default or Event of Default has occurred or results
therefrom and if all scheduled amortization payments and other payments on the

  

 5 

			
		 	 Loans have been made; provided, further that repurchases of Second Lien Debt and the Loans can be made in
exchange for or out of the cash proceeds (including cash of any business acquired in exchange for qualified equity interest) from the sale of qualified equity interests or Asset Sales, to the extent such proceeds are not required to be used to
prepay the Loans pursuant to the mandatory prepayment provisions. Carve-out in covenant to be deleted.
  
 •        Section 6 - Negative Covenants: the following financial covenants to be
added: Minimum Adjusted EBITDA,5 Maximum Debt and Maximum Capex covenants, with the Minimum Adjusted EBITDA covenant being calculated beginning
September 30, 2009 based on the trailing 4 quarters and the Maximum Capex covenant being calculated annually effective December 31, 2009. For the periods ended September 30, 2009 and December 31, 2009, calculations will be made
using constant currency rates as follows: Can$ - 0.80; Aust. $ - 0.65; Euro – 1.275 and British Pound – 1.40. Currency rates in effect on December 31, 2009 and June 30, 2010 will be used for purposes of calculating compliance for
quarters ended during the next succeeding 6 months periods, but such currency rates will not be used retroactively for any periods prior to such date. Minimum Adjusted EBITDA shall be $50 million, calculated quarterly based upon the prior four
quarters effective September 30, 2009. Failure to meet the Minimum Adjusted EBITDA covenant will not be an Event of Default but rather result in a financial penalty of $250,000 per quarter in incremental amortization plus a 50 basis point
increase in the interest rate during the quarters of non-compliance, provided however that if the Adjusted EBITDA is below $42 million it will constitute an Event of Default. The minimum Adjusted EBITDA will be adjusted for
divestitures and acquisitions based upon adjustments calculated by the Company and such adjustments shall be subject to agreed upon procedures performed by the Company’s independent accountants. Maximum Debt shall be $270 million plus
additional debt accrued from (1) the use of PIK and/or (2) acquisitions which would be limited to 2.5 times annual TTM Adjusted EBITDA

  
  

	 5
	 Adjusted EBITDA is consistent with the definition used by the Company in past earnings releases with the addition of
reorganization costs, calculated quarterly based upon the last four quarters. 

  

 6 

			
		 	 acquired (as calculated by the Company and such adjustments shall be subject to agreed upon procedures performed by the
Company’s independent accountants) and as long as such debt is either (a) subordinated to the Loans and the Second Lien Debt in right of payment and rights in the Collateral, with maturity after the 91st day after maturity of the Loans, (b) debt of the acquisition entity that is non-recourse as to Parent or any Restricted Subsidiary other than the Restricted Subsidiary incurring the
subject Indebtedness; provided however, that non-recourse debt issued by any Restricted Subsidiary pursuant to clause (b) shall not exceed $52.5 million in the aggregate, or (c) additional Second Lien Debt so long as such Second Lien
Debt is subordinated in right of payment to the Loans, or any combination of (a), (b) and (c) above, and, in each case, the acquired assets (other than assets of Foreign Subsidiaries) are part of the Collateral securing the Loans in which the
Lenders have a first priority security interest and with respect to acquisitions involving a Foreign Subsidiary the Loans would be secured by a pledge of 65% of the stock of such entity or parent entity; provided further that, in each
such case, the purchase price of any acquisition of assets of a Foreign Subsidiary is funded from Indebtedness permitted to be incurred pursuant to the debt covenant and, as necessary, from one or more of the following sources: (i) Parent equity
issued to the seller; (ii) cash from issuance of Parent equity; and (iii) cash acquired in the acquisition.
  
 •        The Maximum Debt covenant will be required to be maintained at all times as
of the Effective Date; provided, that Indebtedness incurred solely to refinance other Indebtedness shall not be counted in determining compliance with such covenant as long as such Indebtedness is so applied within a reasonable period of time
after being incurred. Maximum Capex shall be $18 million in 2009 and $23 million in 2010, calculated annually effective December 31, 2009, and subject to adjustment for divestitures and acquisitions based upon adjustments calculated by the
Company and such adjustments shall be subject to agreed upon procedures performed by the Company’s independent accountants.
  
 •        Section 6.14(c) - Restriction on Deposit Accounts and Securities Accounts:

 carve-out for a specific account

  

 7 

			
		  	 at BofA (the “BofA Account”) that can hold up to $10 million without being subject to account control
agreement reduced to $5 million.
  
 •        Section 5.1 - Financial Statements: add delivery of monthly financial statements to required financial information deliveries, to be provided to any Lender that requests such monthly
information.

		
	Mandatory Prepayments:	  	Section 2.7 - Mandatory Prepayments: to be revised to include mandatory prepayments from (1) 25% of proceeds of equity issuance (including 25% of the cash of any business acquired in exchange
for equity), (2) proceeds from debt incurrence (other than debt permitted under Limitation on Indebtedness covenant), and (3) 80% of net cash proceeds from any Asset Sale or insurance recoveries not otherwise reinvested in long-term property or
assets of a nature or type that are used in a business (or in a company having property and assets of a nature or type, or engaged in a business) similar or related to the nature or type of the property and assets of, or the business of, the
Borrower and its Restricted Subsidiaries existing on the date of such reinvestment within 180 days or committed to be reinvested provided that a certificate signed by a senior officer of the Company shall be delivered within 10 days after the
expiration of such 180-day period certifying that such proceeds have been so reinvested or a binding commitment has been entered into with respect to such reinvestment.
		
	Repurchase of Term Loans; Successors and Assigns:	  	Sections 2.13 and 9.6 to be modified to make clear that the Parent or any of its affiliates may purchase up to $5 million principal amount of the Loans annually, at less than par, so long as
otherwise permitted under the Loan Agreement without triggering any pro rata provisions, provided that any purchase in excess of $5 million principal amount on an annual basis is made by way of an offer made available to all holders of the Loans on
a pro rata basis. Any such Loans purchased shall be immediately cancelled and under no circumstances may Parent or any of its affiliates vote any rights or obligations with respect to the Loans.
		
	Expenses:	  	All reasonable out of pocket fees and expenses of the Lenders’ professionals (legal, financial, etc.).
		
	Intercreditor Agreement:	  	Modifications to the Indenture governing the Second Lien Debt and the Intercreditor Agreement to make the Second Lien Debt subordinated in right of payment to the Loans on terms customary for
bank debt and second lien debt in the current market in addition to being subordinated on rights against the common Collateral.

  

 8 

			
	 Forbearance Agreement/Amendment of
 Loan
Agreement
	  	The parties will sign an agreement to which the definitive final version of this Term Sheet shall be attached (the date of such agreement being the “Term Sheet Agreement
Date”) and which will provide for the Plan to include the amendment to the Term Loan on the Effective Date on the terms and conditions contained in this Term Sheet.
		
	Conditions Precedent	  	 As a condition precedent to closing of the amendment to the Loan Agreement, the Company shall procure that the following conditions have been
satisfied:
  
 Execution of the release of LCPI as Administrative Agent, to be effective no
later than the Effective Date and execution and delivery of documentation appointing the replacement administrative agent;
  
 Bringdown of the representations and warranties contained in the Loan Agreement (other than the representations relating to No Default (3.7) and Solvency (3.20)). The
representations and warranties shall be true and correct in all material respects on the date of the bring down, as though made on and as of such date (except to the extent they relate to an earlier date);
  
 With respect to the representations and warranties contained in Section 3.8 of the Loan Agreement,
Parent and the Borrower shall represent to the Lenders that all of the real property owned by Parent or its Restricted Subsidiaries is owned free and clear of any Liens, other than those Permitted Liens identified on a schedule to the definitive
amendment agreement;
  
 With respect to the representations and warranties contained in
Section 3.19 of the Loan Agreement, Parent and the Borrower shall represent to the Lenders that the Lenders have a perfected first priority security interest in all of the Collateral other than with respect to the Permitted Liens set forth on a
schedule to the definitive amendment agreement;
  
 The definitive amendment agreement will
contain schedules listing all of the account control agreements and related information for all securities accounts and deposit accounts of the Borrower and the Guarantors, other than the BofA Account;
  
 Delivery of an accounting of the Borrower’s and Guarantors’ intercompany receivables and
payables;

  

 9 

			
		 	 Delivery of account control agreements for all of the Borrower’s and Guarantors’ securities accounts and deposit accounts (other than
(i) deposit accounts and securities accounts holding cash and investment property in an aggregate amount not exceeding $500,000, and (ii) the BofA Account); and
  
 Delivery of a certificate, signed by the chief executive officer of the Company, confirming that the information provided in the Schedules to the Loan Agreement
(including any Schedules to the amendment) are accurate and complete, and (a) all the consents, authorizations, licenses and approvals required in the consummation of the Plan and the execution, delivery and performance by the Company and the
validity against the Company of the amendment and the Loan Documents have been obtained and remain in full force and effect; or (b) no such consents, authorizations, licenses and approvals are required.

  

 10Intellectual Property Transfer Agreement

 Exhibit 10.4 
 Intellectual Property Transfer Agreement 
 This is an agreement between PowerVerde, Inc., hereinafter “PV”,
a public corporation with its principal office at Phoenix, AZ, and Edward C. Gomez, hereinafter “Gomez”, an individual, residing at Benicia, CA, regarding the transfer of ownership of certain patents and other intellectual property owned
by the Vyrex Corporation prior to merger and name change to PowerVerde, Inc. Gomez may assign this agreement to any entity controlled by him at transfer. 
 Whereas PV has changed its principal activities to new technological area and has no further interest or budget to continuing to develop intellectual properties in the pharmacological and neutraceutical fields, but retains ownership of
certain patents and other intellectual property developed prior to its merger, hereinafter “VyrexIP”, which properties are listed on Exhibit A and Exhibit B, and 
 Whereas Gomez has expertise in the fields of medicine and biochemistry and wishes to acquire and develop said VyrexIP and has advanced to PV as loans sums used to pay patent fees and prevent the loss of the VyrexIP.

 PV and Gomez hereby agree that: 
  

	 	1.	PV will assign to Gomez or assigns all patents contained in Exhibits A and B and any information in its possession relating to said intellectual properties.

  

	 	2.	Gomez shall assume ownership of the VyrexIP and shall be responsible for all future fees and professional fees. 

  

	 	3.	Gomez shall provide to PowerVerde, Inc. a residual 20% of net royalty income and any other net income from the Vyrex IP as hereinafter defined in Exhibit C.

  

	 	4.	Gomez shall advise PV in writing of any intent to abandon any part of the VyrexIP and hereby grants to PV the right to recover, without payment, sole ownership of any such
intellectual property. 

  

	 	5.	PV will assign its rights to the name “VYREX” to Gomez for use in conjunction with its activities with VyrexIP. 

  

	 	6.	Gomez hereby forgives all sums previously advanced to PV for the payment of fees on behalf of PV. 

 This agreement is the complete agreement between the parties regarding all services and supersedes any prior discussions and expectations. 
 This agreement may not be changed except in writing and all changes require the consent of both parties. 
 This agreement is
separate and apart from any other agreement between the parties and any agreement with any entity of which either party is a part. 
 This agreement shall be
construed under the laws of the State of California. Any portion of this agreement that is found by a court of competent jurisdiction to be contrary to the Laws of the United States or of the State of California shall be severed from the remainder
of the agreement and shall be null and void without effect upon the remaining portion of the agreement. 
  

							
	 For PowerVerde, Inc.
	 		 	For Edward C. Gomez
				
	By:	 	 /s/ George Konrad
	 		 	 /s/ Edward C. Gomez

	 Director    Date: March 4, 2009
	 		 	Date: March 4, 2009

 Exhibit A: 
 Townsend
and Townsend and Crew LLP 
 2175 N. California Blvd., Suite 600 
 Walnut Creek, CA 94596 
 Phone: 925-472-5000 
  

														
	 ITC Ref Country
ATTY(s) Handling
	  	 Title
	  	 Inventor
	  	Application No.
Filing Date	  	Patent No.
Issue Date	  	 Status Remarks
	  	Estimate of
Anticipated
Costs
	 014742-000100US
 (EGW)
	  	Method for Inhibiting Viral and Retroviral Infections	  		  	07/381132
 07/14/1989
	  	4985465
 01/15/1991
	  	Granted	  		
							
	 014742-000500US
 (EGW)
	  	Tocopherol-Based Anti-Viral Agents and Method of Using Same	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
	  	07/520633
 05/08/1990
	  	5114957
 05/19/1992
	  		  		
							
	 914742-000730US
 (EGW)
	  	Antiviral Agents	  	Hendler, Sheldon S.	  	08/808554
 02/28/1997
	  	5981603
 11/09/1999
	  	 Granted
 Annuity: Next:
 05/09/2011
 Annuity: End of
 Grace (Final
 Deadline):
 11/09/2011
	  	$	2,410
							
	 014742-003200US
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	09/075356
 05/08/1998
	  	6254853
 07/03/2001
	  	 Granted
 Annuity: Next:
 01/03/2009
 Annuity: End of
 Grace (Final
 Deadline):
 07/03/2009
	  	$	1,510
							
	 014742-003210AU
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	37894/99
 05/07/1999
	  	765569
 01/15/2004
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	749
							
	 014742-003210CA
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	2331371
 05/07/1999
	  		  	 Pending
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline).
 05/07/2010
	  	$	685
							
	 014742-003210DE
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	69910560.9-08
 08/20/2003
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity. End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	1,180
							
	 014742-003210EP
 (EGW)
	  	Water Soluble Pro-Drugs of Propofol	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	Granted	  		
							
	 014742-003210ES
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert
A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	770

  

 1 

														
	 ITC Ref Country
 ATTY(s) Handling
	  	 Title
	  	 Inventor
	  	Application No.
Filing Date	  	Patent No.
Issue Date	  	 Status Remarks
	  	Estimate of
Anticipated
Costs
	 014742-003210FR
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	787
							
	 014742-003210GB
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	718
							
	 014742-DG0100US
 (EGW)
	  	Method for Inhibiting Viral and Retroviral Infections	  		  	07/381132
 07/14/1989
	  	4985465
 01/15/1991
	  	Granted	  		
							
	 014742-003210IE
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	99920385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	 Granted
 Annuity Next. 09/07/2009
 Annuity: End of Grace (Final Deadline): 11/07/2009
	  	$	821
							
	 014742-003210IT
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	99926385.4
 05/07/1999
	  	1075489
 08/20/2003
	  	 Granted
 Annuity: Next:
 05/07/2009
 Annuity: End of
 Grace (Final
 Deadline):
 11/07/2009
	  	$	906
							
	 014742-00321OJP
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	2000-548357
 05/07/1999
	  		  	 Pending
 Published
	  		
							
	 014742-003210PC
 (EGW)
	  	 Water Soluble Pro-Drugs
 of Propofol
	  	 Hendler, Sheldon S.
 Sanchez, Robert A.
 Zielinski, Jan
	  	99/10013
 05/07/1999
	  		  	 Pending Nat.
 phase
	  		
							
	 014742-004400JP
 (EGW)
	  	 Water Soluble Prodrugs
 of Propofol for Treatment of
Migraine
	  	Hendler, Sheldon S.	  	2002-518956
 08/14/2001
	  		  	 Pending
 Published
	  		
							
	 014742-004400PC
 (EGW)
	  	 Water Soluble Prodrugs
 of Propofol for Treatment of
Migraine
	  	Hendler, Sheldon S.	  	01/25540
 08/14/2001
	  		  	 Pending Nat.
 phase
	  		
							
	 014742-004400US
 (EGW)
	  	 Water Soluble Prodrugs
 of Propofol for Treatment of
Migraine
	  	Hendler, Sheldon S.	  	09/639015
 08/15/2000
	  	6352234
 03/26/2002
	  	 Granted
 Annuity: Next:
 09/26/2009
 Annuity: End of
 Grace (Final
 Deadline):
 03/26/2010
	  	$	1,510

  

 2 

 Exhibit B: 
 Martin
Fessenmaier. Ph.D. 
 Fish & Associates, PC 
 2603
Main Street, Suite 1050 
 Irvine, CA 92614-6232 
 Direct:
949-705-0973 
  

	(1)	100487.0001US1: “Boron Carbohydrate Complexes and Uses Thereof”; issued as US Pat. No. 5,962,049. 

  

	(2)	100487.0011US2: “Isoflavone Derivatives”; issued as US Pat. No. 6,541,613 

  

	(3)	100487.0011US1: “Isoflavone Derivatives”; issued as US Pat. No. 6,958,156 

  

	(4)	100487.0011US4: “Isoflavone Derivatives”; pending and published as US 2006-0251592 A1 

 Exhibit C: 
 For
purposes of this agreement, “Net Royalty Income” is defined as gross income from commercialization of the patents (Gross Royalty Income) less direct expenses of maintaining and commercializing the patents (Direct Expenses). Direct Expenses
includes all sums expended, accrued, or capitalized directly relating to maintenance or commercialization of the patents. 
 For purposes of this agreement,
“Other Net Income” is defined as gross income from commercialization of the patents (Gross Income), other than royalties, less direct expenses of maintaining and commercializing the patents (Direct Expenses). Direct Expenses includes all
sums expended, accrued, or capitalized directly relating to maintenance or commercialization of the patents.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]